Article
A ruthenium(II)-curcumin compound modulates NRF2 expression balancing the cancer cell death/survival outcome according to p53 status.
Journal of experimental & clinical cancer research : CR - 30 Jun 2020
Garufi Alessia, Baldari Silvia, Pettinari Riccardo, Gilardini Montani Maria Saveria, D'Orazi Valerio, Pistritto Giuseppa, Crispini Alessandra, Giorno Eugenia, Toietta Gabriele, Marchetti Fabio, Cirone Mara, D'Orazi Gabriella
Abstract excerpt
BACKGROUND: Tumor progression and tumor response to anticancer therapies may be affected by activation of oncogenic pathways such as the antioxidant one induced by NRF2 (nuclear factor erythroid 2-related factor 2) transcription factor and the pathways modified by deregulation of oncosuppressor p53. Often, oncogenic pathways may crosstalk between them increasing tumor progression and resistance to anticancer...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.